Ian Wilders, managing director of Labo’Life, a Spanish micro-immunotherapy specialist, discusses the company’s history and the importance of regulatory reform in giving them greater market access and shifting the mindset of doctors. Furthermore, he touches on the company’s international strategy and the importance of a personalized care approach.
Our challenge is defining the regulatory framework in which we are classed, so in the end, patients can receive our therapies
Kyowa Kirin’s head of the South Europe cluster, Norberto Villarrasa, explains the Japanese company’s presence in Spain, its focus on rare diseases and onco-haematology, and comments on the challenges around…
Sanofí’s general manager for Spain, Margarita Lopez Acosta, comments on the company’s “Play to Win” strategy, the presence of the French giant in Spain and the leading role of the…
Faus & Moliner Abogados is a Spanish law firm that has been specializing in pharma and life sciences law since 1997. Founding partner Jordi Faus explains how having a comprehensive…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
What major regulatory trends are emerging in Europe and in Spain? As one of the founding partners of a law firm focused uniquely on the life sciences industry, Faus &…
Over the course of 2022, PharmaBoardroom spoke to over 50 leading stakeholders in the Spanish healthcare and life sciences, from top Spanish scientists to regional ministers of health, multinational affiliate…
See our Cookie Privacy Policy Here